select a format

Single User License
USD 2000 INR 128240
Site License
USD 4000 INR 256480
Corporate User License
USD 6000 INR 384720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Peptic Ulcers-Pipeline Review, H1 2016

Peptic Ulcers-Pipeline Review, H1 2016


  • Products Id :- GMDHC8193IDB
  • |
  • Pages: 57
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Peptic Ulcers-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Peptic Ulcers-Pipeline Review, H1 2016', provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers

The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects

The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Peptic Ulcers Overview 7

Therapeutics Development 8

Pipeline Products for Peptic Ulcers-Overview 8

Peptic Ulcers-Therapeutics under Development by Companies 9

Peptic Ulcers-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Peptic Ulcers-Products under Development by Companies 12

Peptic Ulcers-Companies Involved in Therapeutics Development 13

Ache Laboratorios Farmaceuticos S/A 13

Astellas Pharma Inc. 14

ChoDang Pharm Co., Ltd. 15

Daewoong Pharmaceutical Co., Ltd. 16

Kukje Pharmaceutical Industry Co., Ltd. 17

RaQualia Pharma Inc. 18

Sequella, Inc. 19

Sihuan Pharmaceutical Holdings Group Ltd. 20

Sinil Pharmaceutical Co., Ltd 21

Yooyoung Pharmaceutical Co., Ltd. 22

Peptic Ulcers-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 30

Drug Profiles 31

(ecabet + ranitidine)-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

(lansoprazole + omeprazole)-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

anaprazole sodium-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ASP-6537-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

DWJ-206-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

KJ-14001-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

PDI-39-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

PMKS-005-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

RQ-00000774-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SI-001002 SR-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit Proton Pump for Peptic Ulcers-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules for Gastric Ulcers-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

SQ-109-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

YYD-601-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Peptic Ulcers-Dormant Projects 48

Peptic Ulcers-Discontinued Products 50

Peptic Ulcers-Product Development Milestones 51

Featured News & Press Releases 51

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 51

Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 52

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 52

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 53

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 53

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 54

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 54

Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 55

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Figures

Number of Products under Development for Peptic Ulcers, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 11

Assessment by Monotherapy Products, H1 2016 23

Number of Products by Targets, H1 2016 25

Number of Products by Stage and Targets, H1 2016 25

Number of Products by Mechanism of Actions, H1 2016 27

Number of Products by Stage and Mechanism of Actions, H1 2016 27

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Stage and Molecule Types, H1 2016 30

List of Tables

Number of Products under Development for Peptic Ulcers, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 10

Comparative Analysis by Early Stage Development, H1 2016 11

Products under Development by Companies, H1 2016 12

Peptic Ulcers-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 13

Peptic Ulcers-Pipeline by Astellas Pharma Inc., H1 2016 14

Peptic Ulcers-Pipeline by ChoDang Pharm Co., Ltd., H1 2016 15

Peptic Ulcers-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 16

Peptic Ulcers-Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 17

Peptic Ulcers-Pipeline by RaQualia Pharma Inc., H1 2016 18

Peptic Ulcers-Pipeline by Sequella, Inc., H1 2016 19

Peptic Ulcers-Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 20

Peptic Ulcers-Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 21

Peptic Ulcers-Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 22

Assessment by Monotherapy Products, H1 2016 23

Assessment by Combination Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 29

Number of Products by Stage and Molecule Type, H1 2016 30

Peptic Ulcers-Dormant Projects, H1 2016 48

Peptic Ulcers-Dormant Projects (Contd..1), H1 2016 49

Peptic Ulcers-Discontinued Products, H1 2016 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ache Laboratorios Farmaceuticos S/A

Astellas Pharma Inc.

ChoDang Pharm Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Kukje Pharmaceutical Industry Co., Ltd.

RaQualia Pharma Inc.

Sequella, Inc.

Sihuan Pharmaceutical Holdings Group Ltd.

Sinil Pharmaceutical Co., Ltd

Yooyoung Pharmaceutical Co., Ltd.

Peptic Ulcers Therapeutic Products under Development, Key Players in Peptic Ulcers Therapeutics, Peptic Ulcers Pipeline Overview, Peptic Ulcers Pipeline, Peptic Ulcers Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com